CLOVER HEALTH INVESTMENTS, CORP. /DE
Close on Oct 19, 2026
- Market cap
- $2.42B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $743.17M | $0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $749.00M | $0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $478.00M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $462.30M | $0.00 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $337.00M | $-0.04 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | $356.30M | $0.01 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 6, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 8, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA profitabilitynon-GAAP | Full Year 2026 | $70.00M to $85.00M | Raised |
| Average Medicare Advantage membership | Full Year 2026 | 156,000 to 158,000 | Raised |
| GAAP Net IncomeGAAP | Full Year 2026 | $20.00M to $35.00M | Raised |
| Consolidated Gross Profitnon-GAAP | Full Year 2026 | $525.00M to $555.00M | New |
| Total revenues | Full Year 2026 | $2.92B to $3.00B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Clover Health Investments filed with the SEC
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K/A
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Presentation January 2026 LGTMs: Date: Andrew T. (CEO) LGTM 1/8/26 Peter K. (CFO) LGTM 1.7.26 Karen S. (Legal) LGTM 1.7.26
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Reports Third Quarter 2025 Results
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Comments on 2026 Medicare Advantage Star Ratings and Trajectory for Increasing Profitability into 2027
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
Results of operations · EX-99.1 to Form 8-K
First Quarter 2025 Shareholder Q&A
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period
Regulation FD disclosure · EX-99.1 to Form 8-K
JP Morgan Presentation 2025 January 2025 Slide Deck vF For 8-K / IR Site LGTMs: Date: Peter K. LGTM Legal (Karen / Peter R.) LGTM Andrew T. LGTM
Regulation FD disclosure · EX-99.2 to Form 8-K
Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership
Results of operations · EX-99.1 to Form 8-K
Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
CMS Improves Star Ratings to 3.5 Stars for Clover Health PPO Medicare Advantage Plans for 2025 Payment Year
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health Announces Counterpart Health, a New SaaS and Tech Enabled Services Solution to Bring the Power of CA Technology to all Medicare Advantage Payors and Providers
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health 2024 Leerink Partners Healthcare Crossroads Conference May 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Clover Health Reports Strong First Quarter 2024 Financial Results; Improves Guidance to Target Full-Year 2024 Adjusted EBITDA Profitability
Results of operations · Other events · EX-99.1 to Form 8-K
Clover Health Provides Notice Associated with Previously Disclosed Settlement of Shareholder Derivative Actions
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Other events · EX-99.3 to Form 8-K
Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
Clover Health Provides Business Update and Full-Year 2024 Objectives
Regulation FD disclosure · EX-99.1 to Form 8-K
Clover Health J.P. Morgan Healthcare Conference January 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Clover Health Announces Departure of Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for 2023
Executive or director change · Other events · EX-99.1 to Form 8-K
Clover Health Exits ACO REACH to Accelerate Path to Profitability
Exit or restructuring costs · Material impairment · Other events · EX-99.1 to Form 8-K
Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance
Results of operations · EX-99.1 to Form 8-K